In this Leading opinion we summarise the observational evidence endorsing current guidelines that advocate effective blood pressure control before and during an rtPA infusion and indicate that a more active blood pressure-lowering approach immediately after intravenous thrombolysis appears to be a promising therapeutic option that should be formerly evaluated in a randomised clinical trial setting. Acute ischaemic stroke is a highly treatable neuroemergency and the efficacy of the available treatment is not only related to the speed by which it is administered but also by the effective control of modifiable adverse outcome predictors including elevated blood pressure levels.
© 2011 The Authors. International Journal of Stroke © 2011 World Stroke Organization.